Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | Multiple myeloma treatment strategies: what does the future hold?

Enrique Ocio • 2 Jun 2019
ASCO 2019
Multiple Myeloma Daratumumab Isatuximab

Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses
combination therapy for multiple myeloma in the future. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Enrique Ocio

Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
3:08
Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
Enrique Ocio • 6 Dec 2025
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
1:28
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
Enrique Ocio • 8 Dec 2024
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
1:08
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
Enrique Ocio • 8 Dec 2024
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
1:16
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio • 8 Dec 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Enrique Ocio • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Enrique Ocio • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Enrique Ocio • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Enrique Ocio • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals